The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection

Clinical Therapeutics

Volumn 21, Issue 11, 1999, Pages 1853-1863

  Elion, Richard ^a   Kaul, Sanjeev ^b   Knupp, Catherine ^b   Adler, Myra ^b   Cross, Anne P ^b   Dunkle, Lisa M ^b,c   Kelleher, Thomas ^b  

^a National Hospital Medical Center   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Didanosine (ddI); HIV; Nelfinavir; Safety; Stavudine (d4T)

Indexed keywords

DIDANOSINE; NELFINAVIR; STAVUDINE; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0032796431     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)86733-8     Document Type: Article

References (17)

1. 1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA. 1997;277: 1962-1969.
2. 2. Gazzard BG, Moyle GJ, Weber J, et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 1997;349:1086-1092.
3. 3. Hammer SM, Squires KE, Hughes MD, et al, for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
4. 4. Brankovan V, Tarantini K, Datema R, Chou TC. Strong synergistic anti-HIV activity of a purine and a pyrimidine nucleoside analog, ddI and d4T. In: Program and abstracts of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada. Abstract MCP 128.
5. 3 and who are not eligible for a treatment with ZDV. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 553.
6. 6. Pollard R, Peterson D, Hardy D, et al. Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: Analysis of antiviral effect and safety in a randomized double-blinded trial. In: Program and abstracts of the 10th International Conference on Antiviral Research; April 6-11, 1997; Atlanta, Ga. Abstract ThB 293.
7. 7. Raffi F, Auger S, Billaud E, et al. Antiviral effect and safety of didanosine-stavudine combination therapy in HIV-infected subjects: Interim results of a pilot trial. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 554.
8. 8. Deminie C, Bechtold C, Riccardi K, et al. HIV-1 isolates from subjects on prolonged stavudine therapy remain sensitive to stavudine. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, Canada. Abstract MoA 1115.
9. 9. Coakley E, Gillis J, Pedneault L, et al. Susceptibilities of HIV-1 isolates derived from patients treated with didanosine and stavudine in combination. Antiviral Ther. 1997;2(Suppl 3):95-97.
10. 10. Patick AK, Boritzki TJ, Bloom LA. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vivo. Antimicrob Agents Chemother. 1997; 41:2159-2164.
11. 11. Clumeck N. AVANTI 3: A randomized, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in antiretroviral naive patients. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, III. Abstract 08.
12. 12. Physicians' Desk Reference®. 52nd ed. Montvale, NJ: Medical Economics; 1998:476-480, 768-772, 774-776.
13. 13. Knupp CA, Stancato FA, Papp EA, et al. Quantitation of didanosine in human plasma and urine by high pressure liquid chromatography. J Chromatogr. 1990;533: 282-290.
14. 14. Yates JW, Chalmer B, McKegney FP, et al. Evaluation of patients with advanced cancer using Karnofsky performance status. Cancer. 1980;45:2220-2224.
15. 15. Saimot AG, Landman R, et al. Ritonavir, stavudine (d4T), didanosine (ddI) as a triple combination treatment in antiretroviral-naive patients. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997; Washington, DC. Abstract 246.
16. 16. de Truchis P, Zucman D, Dupont C, et al. Combination therapy with D4T + 3TC + indinavir (IDV) in nucleoside-experienced HIV-infected patients: An open-label study. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 247.
17. 17. Knechten H, Mans-Peine G, Braun P. Combination therapy with stavudine (d4T), lamivudine (3TC), and indinavir (IDV) in antiretroviral naive and experienced HIV infected patients. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Canada. Abstract 263.